Oct. 3 at 5:22 AM
$ARDX Q3 will confirm that it was not Q2 that was exceptional, but Q1. The path to profitability will become visible to even the most ignorant people out there and once profitability is reached, valuation models will start to undergo readjustments towards P/E basis.
Not giving advice, but I will tell you what I will do in the coming weeks before ER: I will build my trading position again that I reduced around 9/25.
$13 is about
$3.1 billion market cap. That is less than a 1.8x multiple on expected peak sales. Yes, patent life is not too long anymore, but a 1.8x multiple is also really low. Plus, it only considers US sales, only X outside medicare, and only the usually conservative guidance issued by the company.
Things will change. This year already, IMHO.
